Saccharomyces boulardii Inhibits EGF Receptor Signaling and Intestinal Tumor Growth in Apcmin Mice

Gastroenterology

Volumn 137, Issue 3, 2009, Pages 914-923

  Chen, Xinhua ^a   Fruehauf, Johannes ^a   Goldsmith, Jeffrey D ^b   Xu, Hua ^a   Katchar, Kianoosh K ^a   Koon, Hon Wai ^c   Zhao, Dezheng ^a   Kokkotou, Efi G ^a   Pothoulakis, Charalabos ^c   Kelly, Ciarán P ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BROXURIDINE; CASPASE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROBIOTIC AGENT; PROTEIN KINASE B; SOMATOMEDIN C RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CELL CULTURE; CELL PROLIFERATION; COLON CANCER; CONTROLLED STUDY; DRUG ACTIVITY; DYSPLASIA; ENZYME ASSAY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; INTESTINE TUMOR; NONHUMAN; ONCOGENE NEU; PRIORITY JOURNAL; SACCHAROMYCES BOULARDII; TUMOR GROWTH; WESTERN BLOTTING;

EID: 69249150150     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.gastro.2009.05.050     Document Type: Article

References (38)

1. Elmer G.W., Surawicz C.M., and McFarland L.V. Biotherapeutic agents. A neglected modality for the treatment and prevention of selected intestinal and vaginal infections. JAMA 275 (1996) 870-876
2. Sullivan A., and Nord C.E. The place of probiotics in human intestinal infections. Int J Antimicrob Agents 20 (2002) 313-319
3. Guslandi M., Mezzi G., Sorghi M., et al. Saccharomyces boulardii in maintenance treatment of Crohn's disease. Dig Dis Sci 45 (2000) 1462-1464
4. Castagliuolo I., LaMont J.T., Nikulasson S.T., et al. Saccharomyces boulardii protease inhibits Clostridium difficile toxin A effects in the rat ileum. Infect Immun 64 (1996) 5225-5232
5. Czerucka D., Dahan S., Mograbi B., et al. Saccharomyces boulardii preserves the barrier function and modulates the signal transduction pathway induced in enteropathogenic Escherichia coli-infected T84 cells. Infect Immun 68 (2000) 5998-6004
6. Czerucka D., Roux I., and Rampal P. Saccharomyces boulardii inhibits secretagogue-mediated adenosine 3′,5′-cyclic monophosphate induction in intestinal cells. Gastroenterology 106 (1994) 65-72
7. Dalmasso G., Cottrez F., Imbert V., et al. Saccharomyces boulardii inhibits inflammatory bowel disease by trapping T cells in mesenteric lymph nodes. Gastroenterology 131 (2006) 1812-1825
8. Dahan S., Dalmasso G., Imbert V., et al. Saccharomyces boulardii interferes with enterohemorrhagic Escherichia coli-induced signaling pathways in T84 cells. Infect Immun 71 (2003) 766-773
9. Chen X., Kokkotou E.G., Mustafa N., et al. Saccharomyces boulardii inhibits ERK1/2 mitogen-activated protein kinase activation both in vitro and in vivo and protects against Clostridium difficile toxin A-induced enteritis. J Biol Chem 281 (2006) 24449-24454
10. Fang J.Y., and Richardson B.C. The MAPK signalling pathways and colorectal cancer. Lancet Oncol 6 (2005) 322-327
11. Jimeno A., and Hidalgo M. Pharmacogenomics of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors. Biochim Biophys Acta 1766 (2006) 217-229
12. de Castro-Carpeno J., Belda-Iniesta C., Casado Saenz E., et al. EGFR and colon cancer: a clinical view. Clin Transl Oncol 10 (2008) 6-13
13. Calonghi N., Pagnotta E., Parolin C., et al. A new EGFR inhibitor induces apoptosis in colon cancer cells. Biochem Biophys Res Commun 354 (2007) 409-413
14. Ponz-Sarvise M., Rodriguez J., Viudez A., et al. Epidermal growth factor receptor inhibitors in colorectal cancer treatment: what's new?. World J Gastroenterol 13 (2007) 5877-5887
15. Marshall J. Clinical implications of the mechanism of epidermal growth factor receptor inhibitors. Cancer 107 (2006) 1207-1218
16. Li Y., Sun X., LaMont J.T., Pardee A.B., et al. Selective killing of cancer cells by β-lapachone: direct checkpoint activation as a strategy against cancer. Proc Natl Acad Sci U S A 100 (2003) 2674-2678
17. Sougioultzis S., Simeonidis S., Bhaskar K.R., et al. Saccharomyces boulardii produces a soluble anti-inflammatory factor that inhibits NF-κB-mediated IL-8 gene expression. Biochem Biophys Res Commun 343 (2006) 69-76
18. Jiang D., Yang H., Willson J.K., et al. Autocrine transforming growth factor α provides a growth advantage to malignant cells by facilitating re-entry into the cell cycle from suboptimal growth states. J Biol Chem 273 (1998) 31471-31479
19. Huang S.M., and Harari P.M. Epidermal growth factor receptor inhibition in cancer therapy: biology, rationale and preliminary clinical results. Invest New Drugs 17 (1999) 259-269
20. Nautiyal J., Rishi A.K., and Majumdar A.P. Emerging therapies in gastrointestinal cancers. World J Gastroenterol 12 (2006) 7440-7450
21. Roberts R.B., Min L., Washington M.K., et al. Importance of epidermal growth factor receptor signaling in establishment of adenomas and maintenance of carcinomas during intestinal tumorigenesis. Proc Natl Acad Sci U S A 99 (2002) 1521-1526
22. Moran A.E., Hunt D.H., Javid S.H., et al. Apc deficiency is associated with increased Egfr activity in the intestinal enterocytes and adenomas of C57BL/6J-Min/+ mice. J Biol Chem 279 (2004) 43261-43272
23. Stern D.F. ERBB3/HER3 and ERBB2/HER2 duet in mammary development and breast cancer. J Mammary Gland Biol Neoplasia 13 (2008) 215-223
24. Pollak M. Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer 8 (2008) 915-928
25. LeRoith D., and Roberts Jr. C.T. The insulin-like growth factor system and cancer. Cancer Lett 195 (2003) 127-137
26. Le Roy C., and Wrana J.L. Clathrin- and non-clathrin-mediated endocytic regulation of cell signalling. Nat Rev Mol Cell Biol 6 (2005) 112-126
27. Miljan E.A., and Bremer E.G. Regulation of growth factor receptors by gangliosides. Sci STKE 2002 (2002) RE15
28. Thiel K.W., and Carpenter G. ErbB-4 and TNF-α converting enzyme localization to membrane microdomains. Biochem Biophys Res Commun 350 (2006) 629-633
29. Hirayama K., and Rafter J. The role of probiotic bacteria in cancer prevention. Microbes Infect 2 (2000) 681-686
30. Rafter J. Probiotics and colon cancer. Best Pract Res Clin Gastroenterol 17 (2003) 849-859
31. Brady L.J., Gallaher D.D., and Busta F.F. The role of probiotic cultures in the prevention of colon cancer. J Nutr 130 (2000) S410-S414
32. Chen X., and Kelly C. Saccharomyces spp. In: Versalovic J., and Wilson M. (Eds). Therapeutic micriobiology: probiotics and related strategies. 1st ed. (2008), ASM Press, Washington, DC 51-60
33. Pothoulakis C., Kelly C.P., Joshi M.A., et al. Saccharomyces boulardii inhibits Clostridium difficile toxin A binding and enterotoxicity in rat ileum. Gastroenterology 104 (1993) 1108-1115
34. Gedek B.R. Adherence of Escherichia coli serogroup O 157 and the Salmonella typhimurium mutant DT 104 to the surface of Saccharomyces boulardii. Mycoses 42 (1999) 261-264
35. Philpott D.J., McKay D.M., Sherman P.M., et al. Infection of T84 cells with enteropathogenic Escherichia coli alters barrier and transport functions. Am J Physiol 270 (1996) G634-G645
36. Buts J.P., Bernasconi P., Vaerman J.P., et al. Stimulation of secretory IgA and secretory component of immunoglobulins in small intestine of rats treated with Saccharomyces boulardii. Dig Dis Sci 35 (1990) 251-256
37. Qamar A., Aboudola S., Warny M., et al. Saccharomyces boulardii stimulates intestinal immunoglobulin A immune response to Clostridium difficile toxin A in mice. Infect Immun 69 (2001) 2762-2765
38. Dalmasso G., Cottrez F., Imbert V., et al. Saccharomyces boulardii inhibits inflammatory bowel disease by trapping T cells in mesenteric lymph nodes. Gastroenterology 131 (2006) 1812-1825